Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708588 · ClinicalTrials.gov registry record · Phase 4
Chewed Versus Integral Pill of Ticagrelor
A Phase 4 study of Percutaneous Coronary Intervention, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT03708588 is a Phase 4 study of Percutaneous Coronary Intervention that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 112 participants, below the 5,216-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03708588, a Phase 4 study of Percutaneous Coronary Intervention, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.
Conditions Studied
Interventions
- DRUG Ticagrelor
Study Locations (1)
Wisconsin
- Aurora Health Care, St. Luke's Medical Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03708588
The ClinicalTrials.gov registry entry for NCT03708588 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,216-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (98% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 1 intervention - of which Ticagrelor is the first listed.
NCT03708588 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03708588 about?
NCT03708588 is a clinical study titled "Chewed Versus Integral Pill of Ticagrelor". Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pi...
What is the current status of trial NCT03708588?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2018-09-19. Estimated completion is 2021-07-31.
What conditions does trial NCT03708588 study?
This clinical trial studies the following conditions: Percutaneous Coronary Intervention.
What interventions are being tested in trial NCT03708588?
The interventions under investigation include: Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT03708588?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03708588 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Percutaneous Coronary Intervention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RECRUITING · Phase 4
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
ACTIVE NOT RECRUITING · NA
-
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
ACTIVE NOT RECRUITING
-
Precision PCI Registry
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.